Oleanic Acid Eugenol Oral Care Hemostasis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current oral care products face challenges in effectively reducing gum bleeding and providing antibacterial efficacy, with some agents posing thromboembolic and drug interaction risks, and a need for natural or botanically-based ingredients.
Innovation Solution
An oral care composition incorporating a hemostatic agent comprising a mixture of oleanic acid and eugenol, which enhances platelet aggregation and provides antibacterial effects, with concentrations ranging from 0.01 to 0.25 weight % oleanic acid and 0.01 to 0.25 weight % eugenol, offering improved gum bleeding relief and antibacterial efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If coagulant agents such as tranexamic acid are used to reduce gum bleeding, then hemostatic effect is improved, but thromboembolic and drug interaction risks increase
Solution Approach 1:
The patent changes the chemical parameters by using oleanic acid (0.02-0.25 wt.%) and eugenol (0.01-0.25 wt.%) instead of tranexamic acid, maintaining hemostatic efficacy while eliminating thromboembolic risks through different mechanism of action (platelet aggregation modulation rather than fibrinolytic inhibition)
Solution Approach 2:
The patent combines oleanic acid and eugenol in a specific formulation to achieve synergistic hemostatic effects, where the composite mixture provides improved platelet aggregation area (at least 10% increase) and reduced platelet rolling velocity (at least 10% decrease) without the harmful side effects of synthetic coagulants
2Reliability
If antibacterial agents are used to reduce plaque and gingivitis, then antibacterial efficacy is improved, but interactions with other active ingredients may reduce effectiveness
Solution Approach 1:
The patent makes the oleanic acid-eugenol mixture serve multiple functions simultaneously: it provides hemostatic effects (increasing platelet aggregation area by at least 10%) and antibacterial effects (reducing plaque and gingivitis), eliminating the need for separate antibacterial agents and avoiding compatibility issues
3Object-affected harmful factors
If natural or botanically-based active ingredients are used, then safety profile is improved, but antibacterial and hemostatic efficacy may be reduced
Solution Approach 1:
The patent optimizes the concentration parameters of natural ingredients (oleanic acid at 0.02-0.25 wt.% and eugenol at 0.01-0.25 wt.%) to achieve efficacy levels comparable to or exceeding synthetic agents, with oleanic acid increasing platelet aggregation area by at least 10% and the mixture providing both hemostatic and antibacterial effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination of oleanic acid and eugenol increases platelet aggregation area by at least 10% and decreases platelet rolling velocity by at least 10%, providing enhanced hemostatic and antibacterial effects, while being safe and effective without additional antibacterial agents.
Implementation Method 1
The hemostatic agent may increase the platelet aggregation area by at least 10 % over a control when tested according to example 1
Implementation Method 2
The hemostatic agent may decrease the platelet rolling velocity by at least 10 % over a control when tested according to example 1
Data Source
AI summary
Oral care compositions including a hemostatic agent, wherein the hemostatic agent includes a mixture of oleanic acid and eugenol. Methods of making and using these compositions are also described.